Search research articles
Contact Us
Filters
Showing results (381-390 of 464) with videos related to
Page
of 47
Sort By:
Journal of Crohn'S & Colitis
|
April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
The Lancet. Gastroenterology & Hepatology
|
December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Silvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastrointestinal Endoscopy
|
April 17, 2018
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
Mark A Samaan, Bo Shen, Mahmoud H Mosli, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2022
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Christopher Ma, Rish K Pai, David F Schaeffer, et al.
The Lancet. Gastroenterology & Hepatology
|
November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Geert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Radiology
|
August 6, 2024
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Florian Rieder, Christopher Ma, Jurij Hanzel, et al.
Eclinicalmedicine
|
November 10, 2025
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease
Virginia Solitano, Jurij Hanžel, Christopher Ma, et al.
Gut
|
May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease
Gregor Novak, Toer Stevens, Tanja Van Viegen, et al.
Page
of 47
Search research articles
Search
Showing results (381-390 of 464) with videos related to
Sort By:
Page
of 47
Journal of Crohn'S & Colitis
|
April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme
Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
The Lancet. Gastroenterology & Hepatology
|
December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Silvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastrointestinal Endoscopy
|
April 17, 2018
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
Mark A Samaan, Bo Shen, Mahmoud H Mosli, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2022
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Christopher Ma, Rish K Pai, David F Schaeffer, et al.
The Lancet. Gastroenterology & Hepatology
|
November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Geert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Radiology
|
August 6, 2024
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Florian Rieder, Christopher Ma, Jurij Hanzel, et al.
Eclinicalmedicine
|
November 10, 2025
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease
Virginia Solitano, Jurij Hanžel, Christopher Ma, et al.
Gut
|
May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease
Gregor Novak, Toer Stevens, Tanja Van Viegen, et al.
Page
of 47